오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified water; microcrystalline cellulose; hyprolose; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 4000 - olmesartan sandoz is indicated for the treatment of hypertension.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: hypromellose; microcrystalline cellulose; lactose monohydrate; hyprolose; purified water; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - olmesartan sandoz is indicated for the treatment of hypertension.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - teicoplanin, quantity: 400 mg - injection, powder for - excipient ingredients: sodium chloride - teicoplanin sandoz is indicated for the treatment of the following serious infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including beta-lactam antibiotics: bone (osteomyelitis); joints (septic arthritis); blood (non-cardiac bacteraemia, septicaemia).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: maize starch; colloidal anhydrous silica; purified talc; pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 400 mg - capsule - excipient ingredients: maize starch; pregelatinised maize starch; purified talc; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.